Physician

John S. Jaggers, M.D.

According to 2025 Medicare claims, John Jaggers, M.D. (NPI: 1568403178) practices pulmonary disease in the Cleveland, TN market, with the plurality of this provider's patient population coming from Bradley, TN. This provider's primary affiliated billing organization is BLUE RIDGE PULMONARY MEDICINE, PC (NPI: 1487601019; TIN: 62-1482378) and primary practice location at 37311-3883.

Jaggers' data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 567 traditional Medicare patients, billed 2,685 HCPCS/CPT codes, and received $154,342 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 4,281 prescription claims across 558 beneficiaries totaling $1,715,273 in drug costs, led by Trelegy Ellipta (Fluticasone/Umeclidin/Vilanter). DME data shows 3,016 claims. Open Payments data shows 108 records totaling $2,495. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a higher plateau to a lower plateau, from $296,284 to $154,342. Concurrently, Part D prescription costs did not follow a clear longitudinal pattern. For DME billing, reported payments declined steadily, from $402,109 to $155,854.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	851	5,194	$296,284
2016	859	5,111	$295,421
2017	832	4,481	$345,075
2018	823	4,102	$231,478
2019	800	4,374	$250,589
2020	722	3,694	$209,574
2021	626	3,252	$200,958
2022	559	2,756	$165,991
2023	546	2,704	$162,109
2024	567	2,685	$154,342

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	532	5,339	$1,343,627
2016	580	5,456	$1,592,718
2017	574	5,227	$1,305,180
2018	576	5,395	$1,840,761
2019	562	5,299	$2,145,562
2020	553	5,130	$2,226,356
2021	526	4,770	$2,058,868
2022	518	4,355	$1,932,830
2023	491	3,966	$1,688,409
2024	558	4,281	$1,715,273

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	1,285	4,402	$407,509
2016	1,266	4,486	$300,256
2017	1,367	4,156	$230,554
2018	1,472	4,322	$252,054
2019	1,535	4,743	$307,508
2020	1,486	5,236	$387,129
2021	1,321	4,692	$374,379
2022	1,076	3,458	$259,949
2023	1,023	3,345	$256,701
2024	947	3,016	$164,009

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	375	563	$84
94729	Test to examine how well the lungs exchange gases	134	147	$38
71046	X-ray of chest, 2 views	140	164	$23
94010	Test to measure expiratory airflow and volume	273	406	$18
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	143	184	$12

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	572	20,384	$421,662
Ofev	Nintedanib Esylate	14	420	$193,126
Sodium Oxybate	Sodium Oxybate	15	375	$173,179
Prolastin C	Alpha-1-Proteinase Inhibitor	12	308	$166,284
Breo Ellipta	Fluticasone/Vilanterol	326	12,630	$161,113

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
E1390	Oxygen concentrator, single delivery port, capable of delivering 85 percent or greater oxygen concentration at the prescribed flow rate	Y	46	351	$27,092
E0466	Home ventilator, any type, used with non-invasive interface, (e.g., mask, chest shell)	Y	N/R	25	$25,308
A7031	Face mask interface, replacement for full face mask, each	N	68	196	$17,208
A7030	Full face mask used with positive airway pressure device, each	N	72	177	$15,970
J7677	Revefenacin inhalation solution, fda-approved final product, non-compounded, administered through dme, 1 microgram	N	N/R	13	$9,899

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	108	$2,495	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for John S. Jaggers, M.D.?

Tedicare shows public-source Medicare data for John S. Jaggers, M.D. (NPI 1568403178), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does John S. Jaggers, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to John S. Jaggers, M.D.?

John S. Jaggers, M.D. is linked to BLUE RIDGE PULMONARY MEDICINE, PC (billing NPI 1487601019) in the available physician profile data.

Does John S. Jaggers, M.D. have Open Payments data?

John S. Jaggers, M.D. has 108 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.